Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novartis Sales Reps Transferred Patient Questionnaires in Investigator-Led Trial
January 20, 2014
-
BUSINESS Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
-
REGULATORY More Manpower, Knowledge Necessary for Giving New Drugs World’s First Approval: PMDA Chief Executive
January 17, 2014
-
REGULATORY Varicella, Adult Pneumococcal Vaccines to Join Japan’s Routine Immunization Program in October
January 16, 2014
-
ORGANIZATION Generic Makers Likely to Disclose Payments to Medical Institutions from Early May
January 15, 2014
-
ORGANIZATION JPWA Chair Weighs Cartel Deal to Unify Tax Display Methods after Sales Levy Hike
January 14, 2014
-
REGULATORY Did Novartis Employees “Willfully” Use Rigged Data in Diovan Ads? Statute of Limitations Will Pose Hurdles to Chase Key Figure
January 10, 2014
-
ORGANIZATION Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
-
REGULATORY MHLW Files Criminal Complaint against Novartis over Diovan Ads
January 9, 2014
-
BUSINESS Former Pfizer EPBU Head Matsumori Joins SBI Biotech as President
January 8, 2014
-
REGULATORY MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
-
REGULATORY MHLW Economic Affairs Official Says Shakeout in Generic Sphere “Inevitable”
January 7, 2014
-
BUSINESS New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
-
ORGANIZATION New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
-
BUSINESS Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
-
BUSINESS Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
-
REGULATORY Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
-
REGULATORY FY2014 Budget: 95.4 Billion Yen for Japan NIH, Development of Novel Drugs
December 25, 2013
-
REGULATORY FY2014 NHI Price Revision Down 5.7% Excluding Tax Adjustments
December 24, 2013
-
BUSINESS Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…